文献速递甲状腺核医学核素与放射性配体治疗

嗜酸细胞性滤泡性甲状腺癌与经典滤泡性甲状腺癌临床影响的比较

Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2020-07-18

该回顾性研究纳入378例接受甲状腺切除术及初始碘-131治疗的滤泡性甲状腺癌患者(嗜酸细胞性126例,经典滤泡性252例),随访中位6.9年。结果显示嗜酸细胞性患者复发率更高(17% vs 8%),无病生存期更短,但疾病特异性生存和总生存无显著差异。

要点

  • 嗜酸细胞性滤泡性甲状腺癌复发率显著高于经典滤泡性癌(17% vs 8%)。
  • 嗜酸细胞性患者无病生存期更短,为其唯一独立预后因素。
  • 两组疾病特异性生存和总生存无显著差异。

核心结论

  • 嗜酸细胞性滤泡性甲状腺癌患者复发更常见,无病生存预后更差,应与经典滤泡性癌分开分类。
  • 但初始碘-131治疗后,两组总生存和疾病特异性生存无显著差异。

研究设计与样本

  • 回顾性评估378例诊断为嗜酸细胞性滤泡性甲状腺癌(N=126)或经典滤泡性甲状腺癌(N=252)的患者。
  • 患者均接受甲状腺切除术和补充碘-131放射性碘治疗,随访中位6.9年(四分位距3.7;11.7年)。
  • 采用单因素和多因素分析识别与疾病相关生存和总生存相关的因素。

主要发现

  • 随访期间嗜酸细胞性患者复发诊断显著更频繁(17% vs 8%;p值0.037)。
  • 嗜酸细胞性患者平均无病生存期缩短为17.9年(95%CI 16.0-19.8),经典滤泡性癌为20.1年(95%CI 19.0-21.1)(p值0.027)。
  • 多因素分析显示嗜酸细胞性为无病生存的唯一独立预后因素(HR 0.502;95%CI 0.309-0.816)。
  • 嗜酸细胞性患者远处转移的碘亲和性显著更低(p值0.014)。
  • 中位随访6.9年(3.7;11.7年)期间,平均疾病特异性生存和总生存无显著差异(p值分别为0.671和0.687)。

临床怎么用

  • 对嗜酸细胞性滤泡性甲状腺癌患者应加强随访监测复发。
  • 嗜酸细胞性滤泡性甲状腺癌远处转移碘亲和性较低,需考虑其他评估或治疗策略。

局限性

  • 为回顾性研究设计。
  • 随访时间中位6.9年,可能不足以评估长期生存差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: There are controversial debates if patients with Hürthle cell carcinoma, also known as oxyphilic or oncocytic cell follicular thyroid carcinoma, have a poorer outcome. In this study, we systematically evaluated the clinical outcome in a large patient cohort following thyroidectomy and initial I-131 radioactive iodine therapy (RIT). METHODS: We retrospectively evaluated a total of 378 patients with diagnosed oncocytic follicular Hürthle cell carcinoma (OFTC) (N = 126) or with classical follicular thyroid carcinoma (FTC) (N = 252). Patients received thyroidectomy and complementary I-131 RIT. Clinical data regarding basic demographic characteristics, tumor grade, persistent disease and recurrence during follow-up, and disease-free, disease-specific, and overall survival were collected during follow-up of 6.9 years (interquartile range 3.7; 11.7 years). Univariate and multivariate analyses were used to identify factors associated with disease-related and overall survival. RESULTS: Before and after matching for risk factors, recurrence was significantly more frequently diagnosed in OFTC patients during follow-up (17% vs. 8%; p value 0.037). Likewise, OFTC patients presented with a reduced mean disease-free survival of 17.9 years (95% CI 16.0-19.8) vs. 20.1 years (95% CI 19.0-21.1) in FTC patients (p value 0.027). Multivariate analysis revealed OFTC (HR 0.502; 95% CI 0.309-0.816) as the only independent prognostic factor for disease-free survival. Distant metastases of OFTC patients were significantly less iodine-avid (p value 0.014). Mean disease-specific and overall survival did not differ significantly (p value 0.671 and 0.687) during follow-up of median 6.9 years (3.7; 11.7 years). CONCLUSIONS: Our study suggests that recurrence is more often seen in OFTC patients. OFTC patients have a poorer prognosis for disease-free survival. Thus, OFTC and FTC behave differently and should be categorized separately. However, patients suffering from OFTC present with the same overall and disease-specific survival at the end of follow-up indifferent to FTC patients after initial RIT.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Wenter V, Albert NL, Unterrainer M, et al. Clinical impact of follicular oncocytic (Hürthle cell) carcinoma in comparison with corresponding classical follicular thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2020. PMID: 32683470. doi:10.1007/s00259-020-04952-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。